Concepedia

Ana M. Aparicio

AM

Statistics

Publications

93

Citations

8.3K

H-Index

48

Active since

1996

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Stanford University

University of Southern California

University of California, San Francisco

The University of Texas Health Science Center at Houston

Ana M. Aparicio is an author at The University of Texas MD Anderson Cancer Center specializing in oncology, medicine, and molecular oncology.

ORCID

Publications per year

1996–2025

93

Publications

93

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2021 · 729 citations · Full text

, , +17

Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer

Ana M. Aparicio, Andrea Harzstark, Paul G. Corn et al. · Clinical Cancer Research · 2013 · 466 citations · Full text

, , +16

The Yeast Genome Directory

A Goffeau, R. Aert, M. L. Agostini-Carbone et al. · Nature · 1997 · 413 citations

, , +12

Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy

Shiping Jiao, Sumit K. Subudhi, Ana M. Aparicio et al. · Cell · 2019 · 383 citations

, , +12

Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer

Likun Li, Styliani Karanika, Guang Yang et al. · Science Signaling · 2017 · 304 citations

, , +17

1–5 of 93